Wall Street set to drop after weak Chinese data; Tariff deadline looms

China’s exports in November shrank for the fourth consecutive month, underscoring persistent pressures on manufacturers from the Sino-U.S. war, but growth in imports may be a sign that Beijing’s stimulus steps are helping to stoke demand.

“Obviously, we can see the Chinese economy is really suffering but this could push them to come up with some sort of a goodwill gesture before the tariffs set in,” said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.

Wall Street gained ground on Friday, driven by a blowout domestic jobs report and optimism around U.S.-China trade negotiations. All three major U.S. stock indexes are hovering within 1% of record highs set two weeks ago.

In a quiet start to the week, market participants are expected to keep a close watch on trade as planned U.S. tariffs on Chinese imports kick in on Dec. 15 that will cover several consumer products, including mobile phones and toys.

Analysts noted that the sideways move on Monday was indicative of investors hoping for a delay in the deadline and expectations of more positive gestures from both sides.

“The markets are telling us that there are hopes for something positive to come up before the deadline. The two sides might just roll back tariffs or even postpone the date but something will happen,” Cardillo said.

Also in focus is the Federal Open Market Committee’s two-day policy meeting, which starts on Tuesday.

At 8:36 a.m. ET, Dow e-minis 1YMcv1 were down 20 points, or 0.07%. S&P 500 e-minis EScv1 were down 2.5 points, or 0.08%, and Nasdaq 100 e-minis NQcv1 were down 10.75 points, or 0.13%.

Among stocks, 3M Co (MMM.N) dropped 1% in premarket trading after Citigroup cut its rating on the industrial conglomerate’s shares to “neutral”.

Macy’s Inc (M.N) fell 2.2% after Goldman Sachs reportedly downgraded shares of the department store operator to “sell”.

In deals, Merck & CO (MRK.N) said it would buy cancer drug developer ArQule Inc (ARQL.O) for $2.7 billion in cash to beef up its portfolio of blood cancer treatments. Shares of ArQule doubled in value following the news.

Reporting by Shreyashi Sanyal in Bengaluru; Editing by Bernard Orr

Our Standards:The Thomson Reuters Trust Principles.
Reuters, 09 Dec, 2019

More Business & Finance News

Private sector can fight poverty through community development: Ahmed Chinoy

View detail

Indexes hit new highs on strong U.S., China economic data

View detail

Disclaimer: All information on this page are taken from third party reliable sources of relevant industry channels, with simple aim just for general information for our users. Hamariweb never endorse or recommend for any trading advice as well as accuracy of data provided here.